Market Overview:
The global injectable drugs for type-2 diabetes market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of type-2 diabetes, rising geriatric population, and technological advancements in the field of injectable drugs for type-2 diabetes. The insulin segment is expected to dominate the global injectable drugs for type-2 diabetes market during the forecast period owing to its high usage rates and growing demand from emerging markets. The exenatide segment is projected to grow at a high CAGR during the forecast period due its benefits over other treatment options available in the market.
Product Definition:
Injectable drugs for type 2 diabetes are medications that you inject into your body with a needle and syringe. They work by helping your body to use the insulin it produces more effectively. This can help to control blood sugar levels and help you to feel better.
Insulin:
Insulin is a hormone, which facilitates the entry of glucose into the blood cells. Insufficient production of insulin by body cells results in rising blood sugar levels and symptoms such as fatigue, headache, back pain or muscle stiffness. The most common type of diabetes is known as juvenile or insulin-dependent diabetes (IDD), caused due to lack of production/secretion of insulin by the pancreas gland.
Exenatide:
Exenatide is a new type 2 diabetes drug that works by helping the body to better absorb sugar from the blood. It's an injectable drug used in Type-2 Diabetes Mellitus and was approved by the FDA in January 2017. The medication was developed by Eli Lilly and Company, which also happens to be one of the leading pharmaceutical companies across the globe.
Application Insights:
The others segment held the largest share of the global injectable drugs for type-2 diabetes market in 2017. This can be attributed to the growing prevalence of other chronic diseases along with type-2 diabetes, which requires longterm care and management. For instance, as per a study published in NCBI in 2018, around 54% adults aged 60 years or above have one or more chronic diseases. Among them, around 20% have at least two chronic conditions and about 8% are living with three or more chronic disorders simultaneously. Thus, increasing incidences of other health issues lead to increased demand for longterm care and management solutions that require less frequent injections over short term therapies that are commonly used for this purpose currently available within the market.
Insulin is still considered as one ofthe most effective therapeutic options available within this segment due to its abilityto control blood glucose levels even after meals when no food is consumed.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in the prevalence of type-2 diabetes and increasing healthcare expenditure. Moreover, an increase in awareness about these drugs and their benefits is also expected to drive growth over the forecast period. Asia Pacific is expected to be one of the fastest growing regions due to rising disposable income, improving economic conditions, expanding middle-class population base along with increasing healthcare spending by countries like China & India.
Moreover, government initiatives for controlling diabetes are also driving regional growth. For instance; In November 2016; The National Institute of Health (NIH) launched a research project that aimed at developing innovative therapies for Type 2 Diabetes through its ongoing clinical trials program - “Diabetes Therapeutics: From Discovery To Disease Management†This initiative will help accelerate progress towards improved treatment options for patients living with this disease globally.
Growth Factors:
- Increasing prevalence of type-2 diabetes
- Growing awareness about the benefits of injectable drugs for type-2 diabetes management
- Rising demand for self-injection devices
- Technological advancements in the field of injectable drugs for type-2 diabetes treatment
- Availability of government funding and initiatives to support research and development activities in the field of injectable drugs for type-2 diabetes
Scope Of The Report
Report Attributes
Report Details
Report Title
Injectable Drugs For Type-2 Diabete Market Research Report
By Type
Insulin, Exenatide, Liragultide, Pramlintide, Others
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
By Companies
AstraZeneca, GSK, Merck, Boehringer Ingelheim, Novo Nordisk, Sanofi, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
222
Number of Tables & Figures
156
Customization Available
Yes, the report can be customized as per your need.
Global Injectable Drugs For Type-2 Diabete Market Report Segments:
The global Injectable Drugs For Type-2 Diabete market is segmented on the basis of:
Types
Insulin, Exenatide, Liragultide, Pramlintide, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- GSK
- Merck
- Boehringer Ingelheim
- Novo Nordisk
- Sanofi
- Eli Lilly
Highlights of The Injectable Drugs For Type-2 Diabete Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin
- Exenatide
- Liragultide
- Pramlintide
- Others
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Injectable Drugs For Type-2 Diabete Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Injectable drugs for type-2 diabetes are medications that are injected into the body. They help to lower blood sugar levels by making the body use insulin more effectively.
Some of the major players in the injectable drugs for type-2 diabete market are AstraZeneca, GSK, Merck, Boehringer Ingelheim, Novo Nordisk, Sanofi, Eli Lilly.
The injectable drugs for type-2 diabete market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Injectable Drugs For Type-2 Diabete Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Injectable Drugs For Type-2 Diabete Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Injectable Drugs For Type-2 Diabete Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Injectable Drugs For Type-2 Diabete Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Injectable Drugs For Type-2 Diabete Market Size & Forecast, 2020-2028
4.5.1 Injectable Drugs For Type-2 Diabete Market Size and Y-o-Y Growth
4.5.2 Injectable Drugs For Type-2 Diabete Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Insulin
5.2.2 Exenatide
5.2.3 Liragultide
5.2.4 Pramlintide
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Online Pharmacy
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Injectable Drugs For Type-2 Diabete Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Injectable Drugs For Type-2 Diabete Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Insulin
9.6.2 Exenatide
9.6.3 Liragultide
9.6.4 Pramlintide
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Online Pharmacy
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Insulin
10.6.2 Exenatide
10.6.3 Liragultide
10.6.4 Pramlintide
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Online Pharmacy
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Insulin
11.6.2 Exenatide
11.6.3 Liragultide
11.6.4 Pramlintide
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Online Pharmacy
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Insulin
12.6.2 Exenatide
12.6.3 Liragultide
12.6.4 Pramlintide
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Online Pharmacy
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Insulin
13.6.2 Exenatide
13.6.3 Liragultide
13.6.4 Pramlintide
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Online Pharmacy
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Injectable Drugs For Type-2 Diabete Market: Competitive Dashboard
14.2 Global Injectable Drugs For Type-2 Diabete Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 GSK
14.3.3 Merck
14.3.4 Boehringer Ingelheim
14.3.5 Novo Nordisk
14.3.6 Sanofi
14.3.7 Eli Lilly
